Vertex Pharmaceuticals (VRTX) closed at $469.55 in the latest trading session, marking a +1.15% move from the prior day.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Vertex Pharmaceuticals’ stock dipped 1.73%, underperforming the S&P 500’s mild loss, despite solid monthly gains. Investors ...

In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Vertex struck a milestone deal with NHS England to make its cutting-edge cystic fibrosis drug ALYFTREK available to eligible ...